Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment
Abstract
The CTX-SLB-MSN targeted nanoplatform has a substantial potential in combinational therapy against colorectal cancer.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
More studies have proven that the CTX-modified nano-drug carrier system has better targeting and exerts a stronger tumor suppressor effect.
“More studies have also proven that the CTX-modified nano-drug carrier system has better targeting and exerts a stronger tumor suppressor effect.196–198”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [196]
Cetuximab is a chimeric monoclonal antibody that selectively binds to EGFR, which can effectively block the activation of EGFR and its downstream signaling pathways, thereby inhibiting EGFR-related development and cancer progression.
“Cetuximab is a chimeric monoclonal antibody that selectively binds to EGFR, which can effectively block the activation of EGFR and its downstream signaling pathways, thereby inhibiting EGFR-related development and cancer progression.196”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [196]
The citation lists haven’t been fetched yet
References 54 · Cited by 38
- Authors
- Chen, R., Huang, Y., Wang, L., Zhou, J., Tan, Y., Peng, C., Yang, P., Peng, W., Li, J., Gu, Q., Sheng, Y., Wang, Y., Shao, G., Zhang, Q., & Sun, Y.
- Affiliations
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
- Nanjing First Hospital (CN)
- Corresponding author
- Zhang, Qing
- Sun, Yueming
- ORCID
- Venue
- Biomaterials Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2021
- Volume
- 9
- Issue
- 6
- Pages
- 2279-2294
- ISSN
- 2047-4830 (ISSN-L)
- 2047-4849
- OpenAlex
- W3122490206
- Cited by
- 38
- References
- 54
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 8 · 2023: 8 · 2022: 7 · 2021: 1
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biomaterials Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Key Research and Development Program of China (2017YFC0908200)
- Jiangsu Provincial Medical Youth Talent (QNRC2016075)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- cetuximab, 5-fluorouracil, colorectal cancer, mesoporous silica nanoparticles, supported lipid bilayers, hybrid nanoplatforms, active targeting, EGFR signaling, cell migration inhibition, tumor invasion, controlled drug release, targeted drug delivery, combination therapy, apoptosis, cell cycle arrest, tumor targeting
- MeSH terms
- Cetuximab, Antineoplastic Agents, Fluorouracil, Humans, Tissue Distribution, Colorectal Neoplasms, Cell Line, Tumor, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
